{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:13:56Z","timestamp":1782749636641,"version":"3.54.5"},"reference-count":86,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:00:00Z","timestamp":1634428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The goal of this investigation was to identify potential risk factors to predict the onset of medication-related osteonecrosis of the jaw (MRONJ). Through the identification of the multiple variables positively associated to MRONJ, we aim to write a paradigm for integrated MRONJ risk assessment built on the combined analysis of systemic and local risk factors. The characteristics of a cohort of cancer patients treated with zoledronic acid and\/or denosumab were investigated; beyond the set of proven risk factors a new potential one, the intake of new molecules for cancer therapy, was addressed. Registered data were included in univariate and multivariate logistic regression analysis in order to individuate significant independent predictors of MRONJ; a propensity score-matching method was performed adjusting by age and sex. Univariate logistic regression analysis showed a significant effect of the parameters number of doses of zoledronic acid and\/or denosumab (OR = 1.03; 95% CI = 1.01\u20131.05; p = 0.008) and chemotherapy (OR = 0.35; 95% CI = 0.17\u20130.71; p = 0.008). The multiple logistic regression model showed that breast, multiple myeloma, and prostate cancer involved a significantly higher risk compared to lung cancer; a significant effect of the combined variables number of doses of zoledronic acid and\/or denosumab (OR = 1.03; 95% CI = 1.01\u20131.06); p-value = 0.03) and exposure to novel molecule treatment (OR = 34.74; 95% CI = 1.39\u2013868.11; p-value = 0.03) was observed. The results suggest that a risk assessment paradigm is needed for personalized prevention strategies in the light of patient-centered care.<\/jats:p>","DOI":"10.3390\/jcm10204762","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T23:05:47Z","timestamp":1634511947000},"page":"4762","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cancer Patients at Risk for Medication-Related Osteonecrosis of the Jaw. A Case and Control Study Analyzing Predictors of MRONJ Onset"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5664-3118","authenticated-orcid":false,"given":"Antonia","family":"Marcian\u00f2","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9549-6111","authenticated-orcid":false,"given":"Ylenia","family":"Ingrasciotta","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morpho-functional Imaging, University of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Isgr\u00f2","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"L\u2019Abbate","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saveria Serena","family":"Foti","sequence":"additional","affiliation":[{"name":"Academic Spin-Off \u201cINSPIRE\u2014Innovative Solutions for Medical Prediction and Big Data Integration in Real World Setting\u201d, Azienda Ospedaliera Universitaria \u201cG. Martino\u201d, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Picone","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Humanitas Istituto Clinico Catanese, 95045 Misterbianco, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Peditto","sequence":"additional","affiliation":[{"name":"Postgraduate School of Oral Surgery, Department of Biomedical, Dental Sciences and Morphofunctional Imaging, University of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Guzzo","sequence":"additional","affiliation":[{"name":"Postgraduate School of Oral Surgery, Department of Biomedical, Dental Sciences and Morphofunctional Imaging, University of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Alibrandi","sequence":"additional","affiliation":[{"name":"Unit of Statistical and Mathematical Sciences, Department of Economics, University of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-1645","authenticated-orcid":false,"given":"Giacomo","family":"Oteri","sequence":"additional","affiliation":[{"name":"Postgraduate School of Oral Surgery, Department of Biomedical, Dental Sciences and Morphofunctional Imaging, University of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,17]]},"reference":[{"key":"ref_1","unstructured":"Bedogni, A., Campisi, G., and Fusco, V. (2021, September 01). Medication Related Osteonecrosis of the Jaw (MRONJ). Available online: https:\/\/www.qeios.com\/read\/594095."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","article-title":"Medication-related osteonecrosis of the jaw: Definition and best practice for prevention, diagnosis, and treatment","volume":"127","author":"Mendes","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Wat, W.Z.M. (2016). Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw. Dent. J., 4.","DOI":"10.3390\/dj4040038"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1210\/endo.141.12.7921","article-title":"In vivo effects of bisphosphonates on the osteoclast mevalonate pathway","volume":"141","author":"Fisher","year":"2000","journal-title":"Endocrinology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/14712598.2017.1263614","article-title":"Denosumab: Targeting the RANKL pathway to treat rheumatoid arthritis","volume":"17","author":"Chiu","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: Implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"ref_8","unstructured":"(2021, September 01). Linee Guida AIOM (Associazione Italiana Oncologia Medica) sul Trattamento Delle Metastasi Ossee. Available online: https:\/\/www.aiom.it\/linee-guida-aiom-trattamento-delle-metastasi-ossee-2019\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2016.1177021","article-title":"Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: New horizons in oncology","volume":"15","author":"Fusco","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00198-015-3335-3","article-title":"Osteonecrosis of the jaw (ONJ): Diagnosis and management in 2015","volume":"27","author":"Khan","year":"2016","journal-title":"Osteoporos Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus","volume":"30","author":"Khan","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00774-020-01195-x","article-title":"Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer","volume":"39","author":"Ueda","year":"2021","journal-title":"J. Bone Miner. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.oraloncology.2018.08.003","article-title":"Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: A systematic review with meta-analyses","volume":"85","author":"Karna","year":"2018","journal-title":"Oral Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.joms.2013.03.019","article-title":"Combination of Zoledronic Acid and Targeted Therapy Is Active But May Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma","volume":"71","author":"Folkmar","year":"2013","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.oooo.2018.11.012","article-title":"Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab\u2014a review","volume":"127","author":"King","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.4317\/medoral.23191","article-title":"Review and update on drugs related to the development of osteonecrosis of the jaw","volume":"25","author":"Eguia","year":"2020","journal-title":"Med. Oral Patol. Oral Y Cir. Bucal"},{"key":"ref_20","first-page":"383","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: A systematic review","volume":"27","author":"Kouri","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Brauner, E., Mezi, S., Ciolfi, A., Ciolfi, C., Pucci, R., Cassoni, A., Battisti, A., Piesco, G., De Felice, F., and Pranno, N. (2021). A New Medical Record Proposal to the Prognostic Risk Assessment for MRONJ in Oncologic Patients: \u201cSapienza Head and Neck Unit\u201d Proposal. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18041851"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bacci, C., Cerrato, A., Dotto, V., Zambello, R., Baril\u00e0, G., Li\u00e7o, A., Semenzato, G., Stellini, E., and Zanette, G. (2021). The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients. Dent. J., 9.","DOI":"10.3390\/dj9020011"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bjoms.2015.10.006","article-title":"Role of intravenous dosage regimens of bisphosphonates in relation to other aetiological factors in the development of osteonecrosis of the jaws in patients with myeloma","volume":"53","author":"Jarnbring","year":"2015","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1007\/s00520-020-05440-x","article-title":"Preventing, identifying, and managing medication-related osteonecrosis of the jaw: A practical guide for nurses and other allied healthcare professionals","volume":"28","author":"Wyngaert","year":"2020","journal-title":"Support. Care Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00520-016-3509-3","article-title":"Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702","volume":"25","author":"Darke","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-Related Osteonecrosis of the Jaws: A Case- Control Study of Risk Factors in Breast Cancer Patients","volume":"26","author":"Kyrgidis","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","year":"1998","journal-title":"Stat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2005.040428","article-title":"Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: Results of a nested matched case-control study","volume":"65","author":"McGwin","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1601-0825.2012.01903.x","article-title":"Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ)","volume":"18","author":"Bedogni","year":"2012","journal-title":"Oral Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.joms.2015.07.019","article-title":"Osteonecrosis of the Jaw in Association with Chemotherapy in the Setting of Cutaneous T-Cell Lymphoma","volume":"74","author":"DeSesa","year":"2015","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clgc.2014.12.002","article-title":"Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature","volume":"13","author":"Fusco","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1532-3382(12)70048-9","article-title":"Risks for Jaw Osteonecrosis Drastically Increases after 2 Years of Bisphosphonate Therapy","volume":"12","author":"Akintoye","year":"2012","journal-title":"J. \u00c9vid. Based Dent. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the Jaw in Cancer after Treatment with Bisphosphonates: Incidence and Risk Factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Rubens","year":"1987","journal-title":"Br. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/sj.bjc.6602767","article-title":"Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease","volume":"93","author":"Berruti","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_38","first-page":"11502","article-title":"Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211. American Society of Clinical Oncology (ASCO) 2019 Annual Meeting","volume":"37","author":"Unger","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Rugani, P., Walter, C., Kirnbauer, B., Acham, S., Begus-Nahrman, Y., and Jakse, N. (2016). Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma. Dent. J., 4.","DOI":"10.3390\/dj4040032"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s00520-020-05748-8","article-title":"Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)","volume":"29","author":"Kizub","year":"2020","journal-title":"Support. Care Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/cncr.24119","article-title":"Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients","volume":"115","author":"Walter","year":"2009","journal-title":"Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e12787","DOI":"10.1111\/ecc.12787","article-title":"Antiresorptive treatment-associated ONJ","volume":"26","author":"Bamias","year":"2017","journal-title":"Eur. J. Cancer Care"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"482","DOI":"10.21037\/atm.2020.03.55","article-title":"Incidence of patients with bone metastases at diagnosis of solid tumors in adults: A large population-based study","volume":"8","author":"Huang","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: Prevention, diagnosis and T management in patients with cancer and bone metastases","volume":"69","author":"Ottoa","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: A meta-analysis of seven randomized controlled trials","volume":"19","author":"Qi","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1007\/s00520-021-06018-x","article-title":"Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases","volume":"29","author":"Ikesue","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00520-017-3629-4","article-title":"Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors","volume":"25","author":"Vigarios","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jbmr.2693","article-title":"Osteonecrosis of the Jaw in the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS)","volume":"31","author":"Zhang","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.oooo.2017.10.010","article-title":"Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort","volume":"125","author":"Mohamed","year":"2018","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11096-020-01018-z","article-title":"Aromatase inhibitors associated osteonecrosis of jaw: Signal refining to identify pseudo safety signals","volume":"42","author":"Neha","year":"2020","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1111\/bcp.14681","article-title":"Medication-related osteonecrosis of the jaw: Analysing the range of implicated drugs from the Australian database of adverse event notifications","volume":"87","author":"Teoh","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-018-4746-8","article-title":"Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: A multicenter retrospective study","volume":"30","author":"Hasegawa","year":"2019","journal-title":"Osteoporos Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00002018-200831050-00001","article-title":"Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: A systematic review","volume":"31","author":"Shim","year":"2008","journal-title":"Drug Saf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/1097-0142(20011101)92:9<2419::AID-CNCR1591>3.0.CO;2-K","article-title":"High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: A mechanism for post-bone marrow transplantation osteopenia","volume":"92","author":"Banfi","year":"2001","journal-title":"Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_57","unstructured":"Guida, A., Grimaldi, A., Ionna, F., Perri, F., and Ascierto, P.A. (2021). New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Review of the literature and single-center experience. Qeios."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ccr3.3418","article-title":"New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy","volume":"9","author":"Guida","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5125\/jkaoms.2019.45.1.3","article-title":"Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology","volume":"45","author":"Zuccarello","year":"2019","journal-title":"J. Korean Assoc. Oral Maxillofac. Surg."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5847429","DOI":"10.1155\/2020\/5847429","article-title":"Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and\/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study","volume":"2020","author":"Zhou","year":"2020","journal-title":"BioMed Res. Int."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the Jaw More Frequently than Bisphosphonates Alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.oooo.2017.12.016","article-title":"Osteonecrosis of the jaw unrelated to medication or radiotherapy","volume":"125","author":"Gadiwalla","year":"2018","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3892\/mco.2016.1100","article-title":"Osteonecrosis of the jaw associated with everolimus: A case report","volume":"6","author":"Yamamoto","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Lee, C.Y. (2016). Medication-Related Osteonecrosis of the Jaw with the mTOR Inhibitor Everolimus in a Patient with Estrogen-Receptor Positive Breast Cancer: A Case Report. Int. J. Oral Dent. Health, 2.","DOI":"10.23937\/2469-5734\/1510033"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","volume":"41","author":"Reid","year":"2007","journal-title":"Bone"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.joms.2008.01.026","article-title":"Inhibition of oral mucosal cell wound healing by bisphosphonates","volume":"66","author":"Landesberg","year":"2008","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1345\/aph.1Q482","article-title":"An Evaluation of the Use of Oral Bisphosphonates and Risk of Esophageal Cancer","volume":"46","author":"Haber","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.tripleo.2011.02.028","article-title":"Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue","volume":"112","author":"Wehrhan","year":"2011","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1601-0825.2010.01720.x","article-title":"Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro","volume":"17","author":"Walter","year":"2010","journal-title":"Oral Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00432-010-0907-7","article-title":"Bisphosphonate-induced osteonecrosis of the jaw: A review of 2400 patient cases","volume":"136","author":"Filleul","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jbmr.37","article-title":"Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice","volume":"25","author":"Kikuiri","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"8768162","DOI":"10.1155\/2016\/8768162","article-title":"Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches","volume":"2016","author":"Lombard","year":"2016","journal-title":"Stem Cells Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.coms.2015.06.001","article-title":"Pathophysiology of Osteonecrosis of the Jaws","volume":"27","author":"Aghaloo","year":"2015","journal-title":"Oral Maxillofac. Surg. Clin."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1359\/jbmr.2004.19.7.1128","article-title":"Osteoclast Differentiation by RANKL Requires NF-\u03baB-Mediated Downregulation of Cyclin-Dependent Kinase 6 (Cdk6)","volume":"19","author":"Ogasawara","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1359\/JBMR.040321","article-title":"RANKL Coordinates Cell Cycle Withdrawal and Differentiation in Osteoclasts through the Cyclin-Dependent Kinase Inhibitors p27KIP1and p21CIP1","volume":"19","author":"Sankar","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3322\/caac.21565","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Hernandez, R.K., Wade, S.W., Reich, A., Pirolli, M., Liede, A., and Lyman, G.H. (2018). Incidence of bone metastases in patients with solid tumors: Analysis of oncology electronic medical records in the United States. BMC Cancer, 18.","DOI":"10.1186\/s12885-017-3922-0"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.oooo.2018.02.003","article-title":"Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention","volume":"125","author":"Owosho","year":"2018","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41415-020-1365-5","article-title":"Deciphering novel chemotherapy and its impact on dentistry","volume":"228","author":"King","year":"2020","journal-title":"Br. Dent. J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jormas.2018.04.006","article-title":"Numb chin syndrome: A reflection of malignancy or a harbinger of MRONJ? A multicenter experience","volume":"119","author":"Fortunato","year":"2018","journal-title":"J. Stomatol. Oral Maxillofac. Surg."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1093\/annonc\/mdv284","article-title":"Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis","volume":"26","author":"Ibrahim","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1200\/JOP.18.00393","article-title":"De-Escalation of Bone-Modifying Agents in Patients with Bone Metastases: The Best of Times and the Worst of Times?","volume":"14","author":"Awan","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Ottewell, P., and Wilson, C. (2019). Bone-Targeted Agents in Breast Cancer: Do We Now Have All the Answers?. Breast Cancer Basic Clin. Res., 13.","DOI":"10.1177\/1178223419843501"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): A phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_85","first-page":"e326","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab vs. zoledronic acid: A systematic review and meta-analysis","volume":"25","author":"Limones","year":"2020","journal-title":"Med. Oral Patol. Oral Y Cir. Buccal"},{"key":"ref_86","first-page":"S7","article-title":"Mining multi-item drug adverse effect associations in spontaneous reporting systems","volume":"11","author":"Harpaz","year":"2010","journal-title":"Breast Cancer"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/20\/4762\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:16:38Z","timestamp":1760166998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/20\/4762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,17]]},"references-count":86,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["jcm10204762"],"URL":"https:\/\/doi.org\/10.3390\/jcm10204762","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,17]]}}}